Amedisys Inc (NASDAQ:AMED) had its target price boosted by Robert W. Baird from $50.00 to $60.00 in a report issued on Friday. They currently have a neutral rating on the health services provider’s stock.
AMED has been the topic of several other reports. Mizuho upgraded shares of Amedisys from a neutral rating to a buy rating and lifted their price objective for the stock from $55.00 to $65.00 in a research report on Thursday, November 2nd. Benchmark Co. upgraded shares of Amedisys from a hold rating to a buy rating and set a $56.00 price objective on the stock in a research report on Thursday, November 2nd. Craig Hallum reiterated a buy rating and set a $68.00 price objective (up from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. BidaskClub upgraded shares of Amedisys from a sell rating to a hold rating in a report on Friday, August 11th. Finally, Jefferies Group LLC restated a buy rating and set a $60.00 price target on shares of Amedisys in a report on Thursday, October 12th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Amedisys currently has a consensus rating of Hold and a consensus price target of $61.00.
Amedisys (AMED) traded up $0.05 during trading on Friday, reaching $56.30. 259,800 shares of the company’s stock traded hands, compared to its average volume of 322,063. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33. The firm has a market capitalization of $1,910.00, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 1.36 and a beta of 0.68. Amedisys has a 12-month low of $38.00 and a 12-month high of $65.91.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The firm had revenue of $380.20 million for the quarter, compared to analyst estimates of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.36 earnings per share. analysts predict that Amedisys will post 2.22 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the business. Federated Investors Inc. PA lifted its position in Amedisys by 2.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after acquiring an additional 44 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Amedisys by 75.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after acquiring an additional 831 shares during the last quarter. CIBC Asset Management Inc acquired a new position in Amedisys during the 2nd quarter worth $230,000. Quantitative Systematic Strategies LLC acquired a new position in Amedisys during the 3rd quarter worth $205,000. Finally, SG Americas Securities LLC lifted its position in Amedisys by 48.7% during the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after acquiring an additional 1,226 shares during the last quarter. 94.62% of the stock is owned by hedge funds and other institutional investors.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.